School of Criminology, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, Canada V5A 1S6.
Subst Abuse Treat Prev Policy. 2013 Jul 9;8:25. doi: 10.1186/1747-597X-8-25.
This paper will determine whether expanding Insite (North America's first and only supervised injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not having such expanded programs for injection drug users.
By analyzing secondary data gathered in 2012, this paper relies on mathematical models to estimate the number of new HIV and Hepatitis C (HCV) infections prevented as a result of additional SIF locations in Montreal.
With very conservative estimates, it is predicted that the addition of each supervised injection facility (up-to a maximum of three) in Montreal will on average prevent 11 cases of HIV and 65 cases of HCV each year. As a result, there is a net cost saving of CDN$0.686 million (HIV) and CDN$0.8 million (HCV) for each additional supervised injection site each year. This translates into a net average benefit-cost ratio of 1.21: 1 for both HIV and HCV.
Funding supervised injection facilities in Montreal appears to be an efficient and effective use of financial resources in the public health domain.
本文将确定在加拿大的更多地点（如蒙特利尔）增设 Insite（北美第一个也是唯一一个监督注射设施）是否比没有此类扩大注射吸毒者计划的医疗保健后果成本更低。
通过分析 2012 年收集的二级数据，本文依靠数学模型来估计由于在蒙特利尔增设新的监督注射设施而预防的新艾滋病毒和丙型肝炎（HCV）感染的数量。
根据非常保守的估计，预计在蒙特利尔增设每个监督注射设施（最多三个）平均每年将预防 11 例艾滋病毒和 65 例丙型肝炎。因此，每年每个新增的监督注射场所可节省 68.6 万加元（HIV）和 80 万加元（HCV）的净成本。这转化为 HIV 和 HCV 的净平均效益成本比为 1.21:1。
在蒙特利尔为监督注射设施提供资金似乎是公共卫生领域中有效和高效利用财政资源的一种方式。
